Resarch Triangle Park, N.C.-based TearScience produces devices focused on treating meibomian gland dysfunction, a leading underlying cause of dry eye disease, Johnson & Johnson said.
TearScience has won FDA clearance for its office-based treatment of meibomian glands and treating MGD, with its devices available in the US and global markets, the company said.
“Dry eye is a significant unmet health need globally, and meibomian gland dysfunction is the cause for more than 60% of people living with this condition. The innovative portfolio from TearScience positively impacts the lives of patients around the world suffering from this chronic condition. These solutions, coupled with our existing contact lens and surgical portfolio, will allow us to help more patients with their vision needs, throughout their lifetime,” J&J Vision companies group chair Ashley McEvoy said in a press release.
Johnson & Johnson said the acquisition will be through its recently acquired Abbott Medical Optics division, and that it expects the acquisition to close by the end of the year.
Last month, J&J said its medical device division is rolling its Pulsar Vascular and Neuravi acquisitions, as well as its existing Codman Neuro neurological portfolio, into a new neurovascular business dubbed Cerenovus.